Innealta Capital’s Vaxcyte PCVX Stock Holding History

Innealta Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-45	Closed	-$3.4K	–	1237
2024 Q2	$3.4K	Buy	+45	New	+$3.06K	﹤0.01%	959

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Innealta Capital's PCVX Position: Q3 2024 in Review

Innealta Capital sold out of Vaxcyte (PCVX) in Q3 2024, closing a stake of 45 shares — an estimated $3.4K sold.

Innealta Capital first reported a position in PCVX in Q2 2024 and held it in 1 quarter. The position peaked at $3.4K in Q2 2024. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

Innealta Capital reported no remaining Vaxcyte position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 45 Vaxcyte shares in Q3 2024, an estimated $3.4K.
Innealta Capital first reported a position in Vaxcyte in Q2 2024 and held it in 1 quarter.
Innealta Capital's Vaxcyte position peaked at $3.4K in Q2 2024.
328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.